Unmet Needs in Treatment Pushes up Pancreatic Cancer Clinical Trials


Published Date : May 15, 2017

ALBANY, New York, May 15, 2017 - MarketResearchReports.biz has added a new report to its repository, titled, “Pancreatic Cancer Global Clinical Trials Review, H1, 2017.” The report furnishes an overview of pancreatic cancer clinical trials scenario, including the trials that are underway at present and their average enrollment in top countries conducted worldwide.

Pancreatic cancer, resulting from the abnormal growth of cells in the pancreas which leads to lump formation in the tissues, prevents proper functioning of pancreas. Pancreatic cancer can be broadly classified depending on whether they affect the endocrine or exocrine functions. Adenocarcinomas, which comprises of almost 95% of all exocrine pancreatic cancers, is the most prevalent form of pancreatic cancer. Other common types of pancreatic cancers are those that affect the endocrine functions such as giant cell carcinomas, squamous cell carcinomas, and adenosquamous carcinomas.

The U.S. records maximum cases of pancreatic cancer every year. In most cases of pancreatic cancer, patients have less than five years to survive on account of the aggressive nature of the virus. This also goes on to show that the pancreatic cancer market has among the highest unmet therapy needs in the oncology market. Only a small fraction of people diagnosed in early stages of the malady have some hope of survival when the tumor can be tackled via drugs, surgical procedures, and chemotherapy. Those in which the cancer has progressed to stage III and stage IV have little chances of survival.

For Sample Copy, click here: http://www.marketresearchreports.biz/sample/sample/1063632

There are hardly any effective cure for pancreatic cancer in the market. Among the very few popular drugs, Gemzar (Gemcitabine) developed by Eli Lilly is considered useful in advanced stage treatments. Abraxane by Celgene, is another therapeutic drug and one of the first to be approved for pancreatic cancer treatment in almost a decade.

To tap into the unmet needs in the pancreatic cancer market a lot of players are developing new treatments. They are currently in the trial phase and the report by MRR sheds light on them. The report, for example, lists Phase I trial by Bellicum Pharmaceuticals to assess BPX-601, a CAR T-cell therapy administered in cases of prostate stem cell antigen (PSCA), in cases of inoperable pancreatic cancer. The drug has been dosed in the first patient in February 2017 and results are keenly awaited.

Bellicum Pharmaceuticals claims this is the first CAR T-cell therapy that could give doctors greater control over cell activity and stop cells from dying when the protein to which they were meant to react against is absent.

In February 2017 again, Targovax announced encouraging overall survival data from the first cohort of patients in its ongoing, phase I/II clinical trial evaluating TG01 (co-administered with GM-CSF) in resected pancreatic cancer given in combination with chemotherapy, gemcitabine, the current standard of care, study CTTG01-01.

To order report Call Toll Free: 866-997-4948 or send an email on sales@marketresearchreports.biz